{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:49:03Z","timestamp":1791823743296,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2013-AdG-339208"],"award-info":[{"award-number":["ERC-2013-AdG-339208"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["EDDCPJT\\100006"],"award-info":[{"award-number":["EDDCPJT\\100006"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Bob Willis Fund"},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Joseph Frazer Trust"},{"DOI":"10.13039\/100015275","name":"Peacock Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR304530"],"award-info":[{"award-number":["NIHR304530"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of polygenic risk scores (PRS) as a risk-stratification tool in cancer screening is an area of increasing interest. The BARCODE1 study is an observational prostate cancer screening study, investigating the use of PRS to risk-stratify people by risk of prostate cancer, with those identified as higher risk invited for prostate cancer screening. Participants of BARCODE1 were invited to take part in a psychosocial sub-study aiming to explore the effect of receiving a polygenic risk score on psychological health, family risk communication and impact on health behaviours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>1300 participants of the BARCODE1 study were invited to complete questionnaires before and after receiving the results of their PRS. A sub-group were invited to participate in one-to-one in-depth semi-structured interviews, conducted in-person, by telephone or video-call. Interviews were audio recorded and transcribed verbatim. Data were analysed using Reflexive Thematic Analysis and the results are reported here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen participants were interviewed and four themes identified; (a) mutual benefit, (b) emotional impact, (c) risk communication and (d) stoical attitudes to health. Participants reported minimal short-term impact on psychosocial health reported following receipt of a PRS. All participants communicated their genetic risk with their spouse\/partner; however, some chose not to inform their children. Participants described themselves as having typical \u2018male\u2019 stoical responses to managing their health and that they did not feel the PRS results had an impact on their health behaviours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Providing an individualised PRS informing future risk of prostate cancer was well received. Overall, participants did not report being psychologically, socially or emotionally affected by receiving this genomic risk information. For those identified as being at higher risk it is important that there is access to healthcare professionals who are competent in discussing the meaning of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03857477\" ext-link-type=\"uri\">NCT03857477<\/jats:ext-link>\n                      , registered 26th Feb 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00347-w","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:06:29Z","timestamp":1784131589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Matthew","family":"Hogben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Myhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"McGrowder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Rageevakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denzil","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benafif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind A.","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"347_CR1","unstructured":"Cancer Research UK. Prostate cancer statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancerheading-Zero. Accessed December 2025."},{"key":"347_CR2","unstructured":"National Prostate Cancer Audit State of the Nation Report. https:\/\/www.npca.org.uk\/wp-content\/uploads\/2025\/01\/NPCA-State-of-the-Nation-Report-2024_v2.pdf. Accessed December 2025."},{"key":"347_CR3","unstructured":"The National Cancer Plan for England. (2026). Accessed https:\/\/www.gov.uk\/government\/publications\/national-cancer-plan-for-england."},{"issue":"10","key":"347_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/jmg-2024-109845","volume":"61","author":"R Hall","year":"2024","unstructured":"Hall R, Bancroft E, Pashayan N, Kote-Jarai Z, Eeles RA. Genetics of prostate cancer: a review of latest evidence. J Med Genet. 2024;61(10):915\u201326.","journal-title":"J Med Genet"},{"key":"347_CR5","unstructured":"Prostate Cancer UK. The PSA test. https:\/\/prostatecanceruk.org\/prostate-information\/prostate-tests\/psa-test.\u00a0Accessed December 2025."},{"issue":"3","key":"347_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","volume":"77","author":"DE Neal","year":"2020","unstructured":"Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, et al. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. Eur Urol. 2020;77(3):320\u201330.","journal-title":"Eur Urol"},{"issue":"1","key":"347_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016;315(1):68\u201376.","journal-title":"JAMA"},{"key":"347_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"issue":"16","key":"347_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1200\/JCO.19.02808","volume":"38","author":"JL Beebe-Dimmer","year":"2020","unstructured":"Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J Clin Oncol. 2020;38(16):1807\u201313.","journal-title":"J Clin Oncol"},{"issue":"12","key":"347_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","volume":"55","author":"A Wang","year":"2023","unstructured":"Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023;55(12):2065\u201374.","journal-title":"Nat Genet"},{"issue":"4","key":"347_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/cancers13040760","volume":"13","author":"EJ Saunders","year":"2021","unstructured":"Saunders EJ, Kote-Jarai Z, Eeles RA. Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers (Basel). 2021;13(4):760.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"347_CR12","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41591-021-01549-6","volume":"27","author":"Polygenic Risk Score Task Force of the International Common Disease Alliance","year":"2021","unstructured":"Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat Med. 2021;27(11):1876\u201384.","journal-title":"Nat Med"},{"key":"347_CR13","doi-asserted-by":"crossref","unstructured":"Benafif S, Ni Raghallaigh H, McGrowder E, Saunders EJ, Brook MN, Saya S, et al. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU Int. 2022;129(3):325\u2013336.","DOI":"10.1111\/bju.15535"},{"issue":"14","key":"347_CR14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E, Brook MN, McGrowder E, Wakerell S, et al. Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. N Engl J Med. 2025;392(14):1406\u201317.","journal-title":"N Engl J Med"},{"key":"347_CR15","doi-asserted-by":"crossref","unstructured":"Gov.Uk: The 10 year health plan for England. 2025. Accessed at https:\/\/www.gov.uk\/government\/publications\/10-year-health-plan-for-england-fit-for-the-future.","DOI":"10.12968\/jokc.2025.10.5.212"},{"issue":"11","key":"347_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/pon.3814","volume":"24","author":"EK Bancroft","year":"2015","unstructured":"Bancroft EK, Castro E, Bancroft GA, Ardern-Jones A, Moynihan C, Page E, et al. The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. Psychooncology. 2015;24(11):1492\u20139.","journal-title":"Psychooncology"},{"issue":"2","key":"347_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ygeno.2013.04.002","volume":"102","author":"KD Graves","year":"2013","unstructured":"Graves KD, Leventhal KG, Nusbaum R, Salehizadeh Y, Hooker GW, Peshkin BN, et al. Behavioral and psychosocial responses to genomic testing for colorectal cancer risk. Genomics. 2013;102(2):123\u201330.","journal-title":"Genomics"},{"issue":"3\u20134","key":"347_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000508963","volume":"23","author":"S Saya","year":"2020","unstructured":"Saya S, McIntosh JG, Winship IM, Clendenning M, Milton S, Oberoi J, et al. A Genomic Test for Colorectal Cancer Risk: Is This Acceptable and Feasible in Primary Care? Public Health Genomics. 2020;23(3\u20134):110\u201321.","journal-title":"Public Health Genomics"},{"issue":"4","key":"347_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10689-020-00185-2","volume":"19","author":"T Yanes","year":"2020","unstructured":"Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerny S, Barlow-Stewart K, et al. Women\u2019s responses and understanding of polygenic breast cancer risk information. Fam Cancer. 2020;19(4):297\u2013306.","journal-title":"Fam Cancer"},{"issue":"4","key":"347_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10689-014-9734-3","volume":"13","author":"EK Bancroft","year":"2014","unstructured":"Bancroft EK, Castro E, Ardern-Jones A, Moynihan C, Page E, Taylor N, et al. It\u2019s all very well reading the letters in the genome, but it\u2019s a long way to being able to write: Men\u2019s interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Fam Cancer. 2014;13(4):625\u201335.","journal-title":"Fam Cancer"},{"issue":"13","key":"347_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample Size in Qualitative Interview Studies: Guided by Information Power: Guided by Information Power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"347_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-69909-7_3470-2","volume-title":"Thematic analysis: A practical guide","author":"V Braun","year":"2022","unstructured":"Braun V, Clarke V. Thematic analysis: A practical guide. London: Sage; 2022."},{"issue":"4","key":"347_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7748\/nr.2024.e1924","volume":"32","author":"E Rowland","year":"2024","unstructured":"Rowland E, Conolly A. A worked example of contextualising and using reflexive thematic analysis in nursing research. Nurse Res. 2024;32(4):17\u201327.","journal-title":"Nurse Res"},{"issue":"3","key":"347_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jgc4.1384","volume":"30","author":"AM Willis","year":"2021","unstructured":"Willis AM, Smith SK, Meiser B, James PA, Ballinger ML, Thomas DM, Yanes T, Young MA. Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: \u2018Another piece of the pie\u2019. J Genet Couns. 2021;30(3):849\u201360.","journal-title":"J Genet Couns"},{"issue":"Suppl 1","key":"347_CR25","first-page":"S88","volume":"49","author":"CH Wade","year":"2019","unstructured":"Wade CH. What Is the Psychosocial Impact of Providing Genetic and Genomic Health Information to Individuals? An Overview of Systematic Reviews. Hastings Cent Rep. 2019;49(Suppl 1):S88\u201396.","journal-title":"Hastings Cent Rep"},{"issue":"4","key":"347_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10689-016-9889-1","volume":"15","author":"MB Daly","year":"2016","unstructured":"Daly MB, Montgomery S, Bingler R, Ruth K. Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam Cancer. 2016;15(4):697\u2013706.","journal-title":"Fam Cancer"},{"key":"347_CR27","doi-asserted-by":"crossref","unstructured":"Rowland E, Oakley C. Exploring the acceptability and benefits of group pretreatment consultations for people receiving systemic anticancer therapy. Cancer Nurs Pract. 2024;23(6).","DOI":"10.7748\/cnp.2023.e1850"},{"key":"347_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.socscimed.2016.07.023","volume":"165","author":"CH Teo","year":"2016","unstructured":"Teo CH, Ng CJ, Booth A, White A. Barriers and facilitators to health screening in men: A systematic review. Soc Sci Med. 2016;165:168\u201376.","journal-title":"Soc Sci Med"},{"issue":"1","key":"347_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13142-012-0149-0","volume":"3","author":"R Nusbaum","year":"2013","unstructured":"Nusbaum R, Leventhal KG, Hooker GW, Peshkin BN, Butrick M, Salehizadeh Y, et al. Translational Genomic Research: Protocol Development and Initial Outcomes following SNP Testing for Colon Cancer Risk. Transl Behav Med. 2013;3(1):17\u201329.","journal-title":"Transl Behav Med"},{"issue":"4","key":"347_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11019-025-10293-4","volume":"28","author":"A Harerimana","year":"2025","unstructured":"Harerimana A, Pillay JD, Mchunu G. The pitfalls of toughing it out: mapping stoic attitudes in cancer patients. A scoping review. Med Health Care Philos. 2025;28(4):775\u201390.","journal-title":"Med Health Care Philos"},{"issue":"3","key":"347_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10897-017-0162-z","volume":"27","author":"MA Young","year":"2018","unstructured":"Young MA, Forrest LE, Rasmussen VM, James P, Mitchell G, Sawyer SD, et al. Making Sense of SNPs: Women\u2019s Understanding and Experiences of Receiving a Personalized Profile of Their Breast Cancer Risks. J Genet Couns. 2018;27(3):702\u20138.","journal-title":"J Genet Couns"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00347-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:54Z","timestamp":1791821154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00347-w","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the Declaration of Helsinki, ethical approval for the BARCODE1 studies (pilot and full study) was granted by the London\u2013Chelsea Research Ethics Committee (REC References 15\/LO\/1992 and 18\/LO\/2166). All participants provided written consent to participate in this study before the start of the interview.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided consent for anonymised quotes to be used for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EB is Guest Editor on the Special Collection focussed on the Integration of Genetics into Oncology Practice for Hereditary Cancer in Clinical Practice. RE has the following conflicts of interest to declare: Honoraria from GU-ASCO, Janssen, University of Chicago, Dana Farber Cancer Institute USA as a speaker. Educational honorarium from Bayer and Ipsen, member of external expert committee to Astra Zeneca UK and Member of Active Surveillance Movember Committee. She is a member of the SAB of Our Future Health. She undertakes private practice as a sole trader at The Royal Marsden NHS Foundation Trust and 90 Sloane Street SW1\u2009\u00d7\u20099PQ and 280 Kings Road SW3 4NX, London, UK. JM is now an employee of Novartis. No other authors have any competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"19"}}